Aggressive blood pressure lowering is safe, but benefit is still hard to prove

Donald G. Vidt, MD
Senior physician, Department of Nephrology/Hypertension, Cleveland Clinic; professor of internal medicine, Ohio State University; member, Sixth Joint National Committee on Detection Evaluation, and Treatment of High Blood Pressure

Marc A. Pohl, MD
Department of Nephrology/Hypertension, Cleveland Clinic; investigator, Hypertension Optimal Treatment Trial*

Address: Donald G. Vidt, MD, Department of Nephrology/Hypertension, A101, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

*The Hypertension Optimal Treatment trial was sponsored by Astra AB, Sweden; Astra Merck Inc., USA; and Hoechst, Argentina.

Donald G. Vidt, MD
Senior physician, Department of Nephrology/Hypertension, Cleveland Clinic; professor of internal medicine, Ohio State University; member, Sixth Joint National Committee on Detection Evaluation, and Treatment of High Blood Pressure

Marc A. Pohl, MD
Department of Nephrology/Hypertension, Cleveland Clinic; investigator, Hypertension Optimal Treatment Trial*

Address: Donald G. Vidt, MD, Department of Nephrology/Hypertension, A101, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

*The Hypertension Optimal Treatment trial was sponsored by Astra AB, Sweden; Astra Merck Inc., USA; and Hoechst, Argentina.

Donald G. Vidt, MD
Senior physician, Department of Nephrology/Hypertension, Cleveland Clinic; professor of internal medicine, Ohio State University; member, Sixth Joint National Committee on Detection Evaluation, and Treatment of High Blood Pressure

Marc A. Pohl, MD
Department of Nephrology/Hypertension, Cleveland Clinic; investigator, Hypertension Optimal Treatment Trial*

Address: Donald G. Vidt, MD, Department of Nephrology/Hypertension, A101, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

*The Hypertension Optimal Treatment trial was sponsored by Astra AB, Sweden; Astra Merck Inc., USA; and Hoechst, Argentina.